ArticleNature communications2022
Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 32 citations in OpenAlex.
- Could β-glucans enhance the immune response to SARS-CoV-2 vaccine by inducing trained immunity and boosting neutralizing antibody production?Frontiers in immunology · 2026Trial
- T cell-associated immunity induced by heterologous recombinant BCG and purified protein vaccination confers cross-variant protection against SARS-CoV-2.Human vaccines & immunotherapeutics · 2026Article
- Fine specificity of antibodies to SARS-CoV-2 nucleoprotein in patients with COVID-19.Immunologic research · 2026Article
- Abortive infection: T cells as early, antibody-independent defenders.Nature reviews. Immunology · 2026Article
- Article
- Structural insights into clonal restriction and diversity in T cell recognition of two immunodominant SARS-CoV-2 nucleocapsid epitopes.Nature communications · 2025Article
- An MVA-Based Vector Expressing the SARS-CoV-2 RBD Fused to N Protein Induces Neutralizing Antibodies and T-Cell Immune Response in Mice.Bulletin of experimental biology and medicine · 2025Article
- Characterization of a novelmSphere · 2025Article
- Antiviral effect of Bromelain combined with acetylcysteine against SARS-CoV-2 Omicron variant.Scientific reports · 2025Article
- Article
- An Update on Anti-COVID-19 Vaccines and the Challenges to Protect Against New SARS-CoV-2 Variants.Pathogens (Basel, Switzerland) · 2025Review
- Fusion protein-based COVID-19 vaccines exemplified by a chimeric vaccine based on a single fusion protein (W-PreS-O).Frontiers in immunology · 2025Article
- Co-immunization with spike and nucleocapsid based DNA vaccines for long-term protective immunity against SARS-CoV-2 Omicron.NPJ vaccines · 2024Article
- Article
- Evaluation of an RBD-nucleocapsid fusion protein as a booster candidate for COVID-19 vaccine.iScience · 2024Article
- Molecular characterization of SARS-CoV-2 nucleocapsid protein.Frontiers in cellular and infection microbiology · 2024Review
- The Key to Increase Immunogenicity of Next-Generation COVID-19 Vaccines Lies in the Inclusion of the SARS-CoV-2 Nucleocapsid Protein.Journal of immunology research · 2024Review
- The role of SARS-CoV-2 nucleocapsid protein in antiviral immunity and vaccine development.Emerging microbes & infections · 2023Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 5 institutions in 2 countries.
Julia T CastroCentro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, 31.310-260, MG, Brazil.
Patrick AzevedoCentro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, 31.310-260, MG, Brazil.
Marcílio J FumagalliPlataforma de Medicina Translacional da Fundação Oswaldo Cruz e Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, 14.040-030, SP, Brazil.ORCID 0000-0002-0207-5423
Natalia S Hojo-SouzaCentro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, 31.310-260, MG, Brazil.
Natalia SalazarCentro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, 31.310-260, MG, Brazil.
Gregório G AlmeidaFundação Oswaldo Cruz-Minas, Belo Horizonte, 30.190-002, MG, Brazil.
Livia I OliveiraFundação Oswaldo Cruz-Minas, Belo Horizonte, 30.190-002, MG, Brazil.
Lídia FaustinoFundação Oswaldo Cruz-Minas, Belo Horizonte, 30.190-002, MG, Brazil.
Lis R AntonelliFundação Oswaldo Cruz-Minas, Belo Horizonte, 30.190-002, MG, Brazil.ORCID 0000-0002-4969-8812
Tomas G MarçalFundação Oswaldo Cruz-Minas, Belo Horizonte, 30.190-002, MG, Brazil.
Marconi AugustoFundação Hospitalar do Estado de Minas Gerais, Belo Horizonte, 31.630-901, MG, Brazil.
Bruno ValiateFundação Oswaldo Cruz-Minas, Belo Horizonte, 30.190-002, MG, Brazil.
Alex FioriniCentro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, 31.310-260, MG, Brazil.
Bruna RattisPlataforma de Medicina Translacional da Fundação Oswaldo Cruz e Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, 14.040-030, SP, Brazil.
Simone G RamosPlataforma de Medicina Translacional da Fundação Oswaldo Cruz e Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, 14.040-030, SP, Brazil.
Mariela PiccinPlataforma de Medicina Translacional da Fundação Oswaldo Cruz e Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, 14.040-030, SP, Brazil.ORCID 0000-0003-2914-9610
Osvaldo Campos NonatoPlataforma de Medicina Translacional da Fundação Oswaldo Cruz e Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, 14.040-030, SP, Brazil.
Luciana BenevidesPlataforma de Medicina Translacional da Fundação Oswaldo Cruz e Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, 14.040-030, SP, Brazil.
Rubens MagalhãesCentro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, 31.310-260, MG, Brazil.
Bruno CassaroCentro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, 31.310-260, MG, Brazil.
Gabriela BurleCentro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, 31.310-260, MG, Brazil.
Daniel DoroCentro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, 31.310-260, MG, Brazil.
Jorge KalilInstituto do Coração, Universidade de São Paulo, São Paulo, 05403-900, SP, Brazil.
Edson DurigonInstituto de Ciências Biológicas, Universidade de São Paulo, São Paulo, 05508-000, SP, Brazil.
Andrés SalazarOncovir, Inc; Orygen, Biotecnologia, São Paulo, 04538-133, SP, Brazil.
Otávia CaballeroOncovir, Inc; Orygen, Biotecnologia, São Paulo, 04538-133, SP, Brazil.
Helton SantiagoCentro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, 31.310-260, MG, Brazil.ORCID 0000-0002-5695-8256
Alexandre MachadoCentro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, 31.310-260, MG, Brazil.
João S SilvaPlataforma de Medicina Translacional da Fundação Oswaldo Cruz e Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, 14.040-030, SP, Brazil.
Flávio da FonsecaCentro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, 31.310-260, MG, Brazil.
Ana Paula FernandesCentro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, 31.310-260, MG, Brazil.
Santuza R TeixeiraCentro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, 31.310-260, MG, Brazil.
Ricardo T GazzinelliCentro de Tecnologia de Vacinas, Universidade Federal de Minas Gerais, Parque Tecnológico de Belo Horizonte, 31.310-260, MG, Brazil. ricardo.gazzinelli@umassmed.edu.ORCID 0000-0003-2427-7699
Universidade Federal de Minas Gerais · BRUniversidade de São Paulo · BRFundação Oswaldo Cruz · BRDeoxi Biotecnologia (Brazil) · BRFundação Hospitalar do Estado de Minas Gerais · BR
Funding
No grant is acknowledged in the PubMed record.
Abstract
Both T cells and B cells have been shown to be generated after infection with SARS-CoV-2 yet protocols or experimental models to study one or the other are less common. Here, we generate a chimeric protein (SpiN) that comprises the receptor binding domain (RBD) from Spike (S) and the nucleocapsid (N) antigens from SARS-CoV-2. Memory CD4
Indexed as
COVID-19SARS-CoV-2AnimalsAntibodies, NeutralizingAntibodies, ViralCD8-Positive T-LymphocytesCOVID-19 VaccinesHumansMiceNucleocapsidNucleocapsid ProteinsSpike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesNucleocapsid ProteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.